Finally, a recent study reported the development of human iPSC-derived NK cells engineered to express an anti-GPRC5D CAR; the resulting off-the-shelf anti-GPRC5D iPSC-derived CAR-NK cells displayed a potent anti-MM cytotoxic activity and could represent a potential therapy for MM [75]. This evidence concerns the gene GPRC5D and Miyoshi myopathy.